Q4 2024 GeoVax Labs Inc Earnings Call Transcript

Mar 27, 2025 / 08:30 PM GMT

Transcript 8-K10-K

Key Points

Positve

Geovax Labs Inc (GOVX) received a significant Project NextGen Award valued at almost $400 million to support their next-generation COVID-19 vaccine, CMO4S1.
The company has completed CGMP product and quality release for their Mpox and smallpox vaccine candidate, GOMVA, with plans for clinical evaluation in the second half of the year.
Geovax Labs Inc (GOVX) is advancing its MVA manufacturing process, which is expected to significantly reduce costs and support decentralized vaccine manufacturing.
The company's COVID-19 vaccine, CMO4S1, is designed to address unmet needs among immunocompromised patients and has shown potential for broader use as a booster to current mRNA vaccines.
Geovax Labs Inc (GOVX) is actively pursuing strategic partnerships and collaborations to support worldwide development and commercialization of their vaccines.

Negative

Geovax Labs Inc (GOVX) reported a net loss of approximately $25 million for 2024, driven by increased manufacturing activities and costs associated with the BARDA contract.
The company's cash balance decreased to $5.5 million at the end of 2024, reflecting significant cash usage in operating activities.
There is uncertainty regarding the ability to sell the Mpox vaccine without clinical testing, despite the urgent global need.
The start of the next Gein trial has been pushed back to mid to late 2025 due to manufacturing and cell line issues.
Geovax Labs Inc (GOVX) faces challenges in securing equitable vaccine access and manufacturing partnerships in low-income countries, despite ongoing discussions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GOVX.OQ - GeoVax Labs Inc
Q4 2024 GeoVax Labs Inc Earnings Call
Mar 27, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome everyone to the Geofa 4th quarter full year 2024 corporate update call. My name is Michelle and I'll facilitate today's call.

With me are David Dodd, Chairman CEO Mark Reynolds, Chief Financial Officer, Mark Newman, PhD, Chief Scientific Officer, Kelly McKee, MDMPH, Chief Medical Officer.

And John Sharkey, PhD Vice President Business Development. At this time, all participants are to listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded.

At this time I've turned the call over to Max Gattaca of Precision AQ.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.